FairValu
Zoetis Inc.

Zoetis Inc.

ZTSNYSE
Drug Manufacturers - Specialty & Generic • Healthcarezoetis.com
Current Price
$72.140.00%
Market Cap
$29.81B
Shares Outstanding: 413.22M
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for ZTS

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for ZTS

Checking Factor Scorecard coverage

Financial statement coverage is being verified before factor scores are shown.

Price Chart

NYSE:ZTS via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
1.4%
Weak
Revenue CAGR 3Y
-
Forward Revenue Growth
-2.5%
Declining
Revenue Acceleration
-3.9%
Slowing

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
6.32
Profitable
EPS Growth
0.2%
Weak
EPS CAGR 3Y
-
EPS Surprise
1.0%
Beat
Forward EPS
6.21
Profitable
Fwd Revenue Growth
-2.5%
Forward EPS Growth
5.2%
Moderate

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
71.5%
High
Operating Margin
-
Net Margin
27.5%
High
Margin vs Trend
-
ROE
83.1%
Excellent
ROIC
-

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$2.37B
Positive
FCF Growth
6.6%
Moderate
FCF Margin
-
Cash Conversion
1.10x
Strong

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
11.62x
Low
EV / FCFSupporting
15.80x
Typical
Trailing P/ESupporting
11.42x
Low
Price / SalesContext
3.13x
Typical

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
3.08x
Healthy
Quick Ratio
1.58x
Healthy
Debt / Equity
2.87x
High Leverage
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Buyback Yield
12.2%
Strong
Net Insider Buys
+3
Buying

Peer Comparison

TickerPrice
ZTSZoetis Inc.
$72.14
Company Profile

About the Company

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Next Earnings Date

Nov 3, 2026

Loading latest news...

Revenue segmentation

Loading segment disclosures…

Zoetis Inc. (ZTS) AI Stock Summary